Why Equity Incentives Matter and Why They Are Often Poorly Structured
Equity is the most powerful retention and motivation tool available to a startup, and also one of the most frequently misused. The choice of equity incentive vehicle has material tax consequences for both the employee and the employer, and a scheme that is poorly structured at the outset can result in unexpected income tax and NIC charges at the worst possible moment: at exit, when employees finally realise the value they have spent years building.
The good news is that the UK has one of the most generous startup equity incentive regimes in the world. The Enterprise Management Incentive (EMI) scheme in particular is highly favourable compared to equivalent structures in the United States, Germany, or France. The bad news is that qualifying for EMI is not automatic, the rules have genuine complexity, and a significant number of startup option schemes are set up incorrectly, often with valuations that do not reflect market value or with option agreements that inadvertently exclude tax advantages.
This article covers all five main equity incentive vehicles in sufficient detail to inform the CFO's and founder's decisions about which to use and when. It is not a substitute for specialist share scheme advice from a tax adviser or solicitor, particularly for EMI valuations and for Growth Share structuring.
Enterprise Management Incentives (EMI)
EMI is the gold standard for qualifying UK startups and small companies. It offers the most favourable tax treatment of any UK equity incentive and is specifically designed for companies that cannot compete with large employers on salary.
Qualifying Criteria
Not all companies qualify. The key conditions are: the company must be independent (not under the control of another company); it must be UK-based or have a UK permanent establishment; gross assets must not exceed £30 million; full-time equivalent employees must be fewer than 250; and the company must carry on a qualifying trade. That last requirement is the critical catch for many fintech businesses: financial services activities are excluded trades under the EMI rules. A company whose principal activity is the provision of financial services — including most FCA-regulated activities — may be disqualified from EMI. This requires specific analysis; some fintech companies carry on ancillary regulated activities alongside a qualifying core trade and may still qualify. Others are entirely excluded.
Key Limits
The individual limit is £250,000 of market value of shares over which options are held at the time of grant, measured using the EMI-agreed valuation. The company limit is £3 million of total outstanding EMI options at any time.
Tax Treatment
EMI's tax advantages are substantial. On grant: no income tax or NIC arises, provided the option is granted at or above market value (as agreed with HMRC via a Section 431 valuation). On exercise: no income tax or NIC arises, provided the exercise price equals or exceeds the market value at grant and the option was granted at market value. On disposal: the employee pays capital gains tax on the difference between the disposal proceeds and the exercise price. Critically, Business Asset Disposal Relief (BADR, formerly Entrepreneurs' Relief) is available, reducing the CGT rate to 10% on the qualifying gain, subject to the lifetime limit. Note: BADR rates are increasing to 14% from April 2025 under the Autumn Budget 2024, rising further to 18% from April 2026.
Company Share Option Plan (CSOP)
CSOP is the tax-advantaged option scheme available to all companies — including those excluded from EMI. There is no restriction on excluded activities, no gross assets test, and no FTE limit. CSOP is therefore the primary vehicle for financial services businesses and larger companies that have grown beyond the EMI qualifying thresholds.
The individual option value limit was doubled from £30,000 to £60,000 from April 2023 under the Finance Act 2023 changes, significantly increasing the utility of CSOP for incentivising senior hires. Tax treatment: no income tax on grant (if at market value); no income tax on exercise (if granted at market value); CGT on disposal at the normal CGT rates (20% higher rate, or 18% / 24% for residential property — but options over company shares are typically taxed at 20%). BADR may be available on disposal from CSOP if the qualifying conditions are met, but the conditions are more stringent than for EMI.
Growth Shares
Growth Shares are a class of shares (not options) with a hurdle price set at or above the current market value of the company. The recipient pays market value for the shares at grant, but because the hurdle price means they only participate in value above the hurdle, that market value is typically very low — often a few pence per share. Gains above the hurdle are then treated as capital on disposal, subject to CGT.
Growth Shares are particularly useful where: (a) the company does not qualify for EMI; (b) the individual limit or company limit under EMI is exhausted; or (c) the company wishes to grant equity to advisers or contractors who would not be employees eligible for EMI. The valuation of Growth Shares requires care. A "discount for lack of marketability" is typically applied to reflect the illiquidity of shares in a private company, and the hurdle price must be set at a level that HMRC would accept as fair market value. An incorrect valuation can result in HMRC treating the discount from market value as employment income, triggering an unexpected income tax charge.
Restricted Stock Units (RSUs)
RSUs are common in US-listed companies and increasingly used by US-headquartered businesses operating in the UK. An RSU is a promise to deliver shares (or their cash equivalent) on vesting, rather than an option to buy shares at a fixed price. The key tax consequence in the UK is that income tax and employee NIC arise at vesting on the market value of shares at that date. This means the tax event is at vesting, not at a future sale. RSUs are therefore less tax-efficient than EMI options for most UK employees, particularly at Series A and B stage where company values are relatively low at grant but expected to increase significantly by vesting.
Unapproved Options
An unapproved option (also called a non-tax-advantaged option) is simply an option that does not qualify for any of the HMRC-approved scheme treatments. There is no cap on the value of options that can be granted. The disadvantage is the tax treatment: income tax and employee NIC arise at exercise on the spread between the market value at exercise and the exercise price. Employer NIC also arises. For early-stage companies where the market value at exercise might be very high, the income tax and NIC liability at exercise can be substantial and may arise before the employee has liquid proceeds to pay it.
Unapproved options are used where no other vehicle is available (the company does not qualify for EMI, CSOP limits are exhausted, and Growth Shares are not suitable) or where the company does not wish to complete the HMRC notification and valuation process.
Comparison Table
| Scheme | Who qualifies | Tax on exercise | Tax on disposal | Limits |
|---|---|---|---|---|
| EMI | Qualifying companies (<£30m gross assets, <250 FTE, qualifying trade, independent) | None (if at MV) | CGT; BADR at 14% from Apr 2025 | £250k per employee; £3m company |
| CSOP | Any company; no excluded activity restriction | None (if at MV) | CGT at standard rates | £60k per employee (from Apr 2023) |
| Growth Shares | Any company; advisers and contractors included | N/A (shares, not options) | CGT on gain above hurdle; BADR may apply | No statutory limit; valuation essential |
| RSUs | Any company; common in US groups | Income tax and NIC at vesting | CGT on gain after vesting value | No statutory limit |
| Unapproved options | Any company; no qualifying conditions | Income tax and NIC on spread | CGT on gain after exercise value | No statutory limit |
IFRS 2 Accounting for All Share Schemes
IFRS 2 Share-based Payment applies to all equity incentive arrangements, regardless of whether they are HMRC-approved. It requires that the fair value of equity instruments granted to employees be recognised as a charge in the P&L over the vesting period, with a corresponding credit to equity reserves.
For options (EMI, CSOP, unapproved), the fair value is measured at the grant date using an option pricing model — typically Black-Scholes for standard vesting arrangements or a Monte Carlo simulation for market-based performance conditions. Key inputs include: share price at grant, exercise price, expected volatility, risk-free rate, expected dividend yield, and expected option term. For Growth Shares, the fair value is the price paid by the recipient (typically a small discount to the hurdle-adjusted market value).
The IFRS 2 charge has no cash impact. It is a non-cash P&L expense. However, it is often excluded from EBITDA calculations, and investors and analysts will want to understand the charge and its basis. For a company with a large EMI pool that is growing in value, the IFRS 2 charge can be material relative to EBITDA. The charge is required to be disclosed in the statutory accounts with key assumptions, and a reconciliation of share option movements.
"The CFO's job with equity incentives is not to minimise dilution — that is the shareholder's job. The CFO's job is to ensure that the scheme is correctly structured, properly valued, fully expensed under IFRS 2, and clearly communicated to the people it is designed to retain."
Practical Guidance by Stage
For pre-seed and seed stage companies that qualify for EMI: implement an EMI scheme as soon as possible after incorporation. The cost of setting up a well-drafted EMI scheme is £5,000 to £10,000 in legal fees and an HMRC valuation; this is low relative to the tax benefit. Establish an HMRC-agreed market value for the shares as the exercise price, so that the employees have a locked-in tax-efficient gain from day one.
For Series A companies that are approaching the EMI company limit (£3m outstanding): plan ahead. Once the £3m limit is reached, new grants cannot be made under EMI. CSOP, Growth Shares, or a combination may be required for senior hires. This is a governance issue: the board should know the current EMI headroom and have a plan for what happens when it is exhausted.
For financial services businesses excluded from EMI: CSOP up to the £60,000 individual limit, Growth Shares for amounts above that limit, and unapproved options where the flexibility of unlimited grants is required. The tax profile is less favourable than EMI, but CSOP and Growth Shares are materially better than unapproved options for employees with significant expected gains.
Key Takeaways
- EMI is the most tax-efficient equity incentive for qualifying UK startups: no income tax on grant or exercise if at market value, CGT at BADR rates on disposal. But financial services companies may be disqualified as an excluded activity.
- CSOP is available to all companies including financial services firms; the individual limit doubled to £60,000 from April 2023. It is the primary vehicle for regulated businesses that cannot use EMI.
- Growth Shares allow participation in value above a hurdle price and can be used alongside EMI/CSOP where statutory limits are reached, or for advisers and contractors. Valuation by a specialist is essential to avoid an unexpected income tax charge.
- RSUs and unapproved options both trigger income tax and NIC at vesting or exercise, making them materially less tax-efficient for high-growth companies. They are used where no other vehicle is available or appropriate.
- BADR rates are rising: 14% from April 2025 and 18% from April 2026. This is relevant for EMI option holders with material gains who have flexibility on timing of exercise and disposal.
- IFRS 2 requires a non-cash P&L charge for all share-based payment arrangements, measured at fair value at grant. This must be correctly modelled into financial forecasts and clearly disclosed in statutory accounts.
- Never grant EMI options at below market value. Always agree the HMRC-acceptable valuation first, set the exercise price at or above it, and obtain HMRC confirmation of the valuation before grant.
